Paradigm Biopharmaceuticals

Sign up to get the latest news, announcements and updates from Paradigm delivered straight to your inbox, and be the first to hear as our research advances.

Home

About us

Pipeline

Clinical Trials

Peer-Reviewed Publications

Cardiovascular

Respiratory

Lysosomal Storage Diseases

Inflammatory Arthritis

Osteoarthritis

Our Board

Executive Team

Corporate Governance

Analyst Reports

Market Data

Webinars

Announcements

News & Videos

Contact

Archivo

upload.jpg

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) (“Paradigm” or “the Company”) a late-stage drug development company focused on delivering new therapies to address unmet medical needs,  is pleased to invite shareholders to attend an investor presentation from the Company as part of the TechKnow Invest Webinar Series.

The webinar, occurring 12pm AEDT / 9am AWST on 2 December 2025 will be held via Zoom and registration is available through the following link:

https://us02web.zoom.us/webinar/register/WN_mmMSYbxbRBuSzSlqQrZFLg#/registration

The presentation, which will be delivered by Managing Director, Paul Rennie will provide an update on the Company. Paradigm’s current focus is developing iPPS for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3).

Mr Rennie will also participate in a moderated Q&A session where webinar attendees will have the opportunity to submit questions directly to company representatives.

A recorded copy of the webinar will be made available following the event.

Investor Webinar Invitation